Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of “Moderate Buy” from Analysts

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has received an average rating of “Moderate Buy” from the nineteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $60.65.

IONS has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Piper Sandler decreased their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Royal Bank of Canada restated an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, September 26th. Finally, Wells Fargo & Company decreased their price objective on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,194 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares in the company, valued at approximately $1,278,396.96. This trade represents a 3.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the transaction, the chief executive officer now owns 167,393 shares in the company, valued at $6,369,303.65. The trade was a 3.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,877 shares of company stock valued at $299,578 over the last ninety days. 2.71% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IONS. GAMMA Investing LLC boosted its holdings in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after acquiring an additional 303 shares during the period. Itau Unibanco Holding S.A. bought a new position in Ionis Pharmaceuticals in the 2nd quarter worth about $37,000. Capital Performance Advisors LLP purchased a new position in Ionis Pharmaceuticals during the 3rd quarter valued at about $40,000. Prospera Private Wealth LLC purchased a new position in Ionis Pharmaceuticals during the 3rd quarter valued at about $42,000. Finally, Quantbot Technologies LP bought a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at about $51,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $34.97 on Wednesday. The company has a market capitalization of $5.52 billion, a P/E ratio of -14.33 and a beta of 0.35. The company has a fifty day moving average price of $36.52 and a 200-day moving average price of $41.85. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. Ionis Pharmaceuticals has a 52-week low of $33.33 and a 52-week high of $54.44.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.